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Goals
1. Perform a chemical screen to find
drugs that reduce the volume/growth
of tumors
2. Safer and more effective way to
combat cancer
3. Understand the biological pathways
and their effect on Drosophila models
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Background Information
• Glioblastoma multiforme
– Most malignant form of the highest-grade glioma
– Poor prognosis

Tyrosine Kinase Inhibitors
• Tyrosine kinase inhibitors
– Blocks function of epidermal growth factor receptor (EGFR)

• EGFR
– Serves as an “antenna,” receiving signals from other cells
and the environment that tell the cell to grow and divide
– Larger amount on surface of cancer cells
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Experimental Model
• Drosophila melanogaster model
– Has been shown to accurately demonstrate
human glioma growth
– Shares 70 percent of disease genes with humans;
including 2 most frequent oncogenic pathways
• Ras/MAPK: Oncogenic mutation
• Pi3K: Growth regulatory

Experimental Model
• Drosophila melanogaster model
– Two types of flies:
• 𝑃𝑡𝑒𝑛𝑅𝑁𝐴𝑖 , 𝑟𝑎𝑠 𝑣12
– 𝑃𝑡𝑒𝑛𝑅𝑁𝐴𝑖 works to shut off a tumor-suppressor
gene (Pten)
– 𝑟𝑎𝑠 𝑣12 works to promote tumor growth

• Repo GFP
– Repo works to drive the tumor progression,
cancer growth cannot progress without it
– GFP allows the glia cells in the brain to fluoresce under
UV light

What are Pathways?
• Definition:
– A series of actions
among molecules
within a cell that
causes a certain
change within that cell
– Gene-regulation
Pathway

Cancer Progression
𝑃𝑡𝑒𝑛𝑅𝑁𝐴𝑖 , 𝑟𝑎𝑠 𝑣12

Pi3K
Activation

Cell

𝑟𝑎𝑠 𝑣12
Activation
Tumor

Cell
Repo
(gal4 driver)

GFP
Activation
Repo GFP

Cell

Drug Screen Process
2.

1.
Reestablishing fly
colonies.

4.

3.
Collecting female
virgins from
𝑃𝑡𝑒𝑛𝑅𝑁𝐴𝑖 , 𝑟𝑎𝑠 𝑣12
stock.

Day 3:
Collecting larvae
from cross and
placing into vials
containing drug
laced food.

Crossing 𝑃𝑡𝑒𝑛𝑅𝑁𝐴𝑖 ,
𝑟𝑎𝑠 𝑣12 virgins with
Repo GFP males.

5.
Day 5 and 6:
Recollecting,
dissecting,
mounting, and
imaging the larvae.

Results
• P1G8
Repo control brain

Glioma brain

Our screen: 300 µM

Results (cont.)
• P1G10
Glioma

Previous: (10µM)

Our screen: 300 µM

Future Directions
• EC50 Curve
– Determines at what point the drug kills
50% of the population
– Why is this important?

• Perform western blots
– Determine proteins effected by the drugs,
how pathways are affected

• Mammalian cell trials with
Dr. Pitychoutis

Future Directions (cont.)
• Additional preliminary screenings
• AZD 3759 (ongoing)
Repo control brain

Glioma brain

Glioma brain + Lapatinib (GW572016) Ditosylate

Future Directions (cont.)
• Gefitinib
– In clinical phase 4, showing promise
Glioma

Glioma + Gefitinib (10uM)

Roadblocks
• Reestablishing fly
colonies
– Male : Female
Ratios
– Live organisms

• Virgin collection

Conclusion
• PIG8 & P1G10 at 300 µM
– May be too toxic for larvae
– Next step will be EC50 curve

• Utilize data to better understand how
these tyrosine kinase inhibitors affect
tumor growth/volume
– Will help improve therapies and thereby
prognosis of glioma patients
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